Nevada
|
0-30379
|
88-0425691
|
||
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
||
of Incorporation)
|
Identification Number)
|
|||
3661 Horseblock Road
|
||||
Medford, NY 11763
|
||||
(Address of principal executive offices)
|
||||
631-924-1135
|
||||
(Registrant’s Telephone Number)
|
|
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
99.1
|
Press Release entitled “Chembio Diagnostics Reports Second Quarter 2012 Financial Results” dated November 13, 2012.
|
99.2
|
Presentation entitled “Investor Presentation November 2012” dated November 13, 2012.
|
99.3
|
Investor Fact Sheet posted to the company website dated November 13, 2012.
|
Exhibit Number
|
Description
|
99.1
|
Press Release entitled “Chembio Diagnostics Reports Second Quarter 2012 Financial Results” dated November 13, 2012.
|
99.2
|
Presentation entitled “Investor Presentation November 2012” dated November 13, 2012.
|
99.3
|
Investor Fact Sheet posted to the company website dated November 13, 2012.
|
·
|
Total revenues of $5.01 million, down 15% compared with $5.92 million
|
·
|
Product sales of $4.75 million, down 14% compared with $5.53 million
|
·
|
Operating loss of $485,000, compared with operating income of $479,000
|
·
|
Net loss of $292,000 or $0.04 per share, compared with net income of $476,000 or $0.06 per diluted share
|
·
|
Total revenues of $17.74 million, up 35% compared with $13.17 million
|
·
|
Product sales of $16.92 million, up 47% compared with $11.52 million
|
·
|
Operating income of $747,000, compared with $537,000
|
·
|
Net income of $450,000 or $0.05 per diluted share, compared with net income of $528,000 or $0.06 per diluted share
|
Chembio Diagnostics, Inc. & Subsidiary
|
|||||||||
Summary of Condensed Consoldidated Results of Operations
|
|||||||||
UNAUDITED
|
|||||||||
For the three months ended
|
For the nine months ended
|
||||||||
September 30, 2012
|
September 30, 2011
|
September 30, 2012
|
September 30, 2011
|
||||||
Net product sales
|
$ 4,745,094
|
$ 5,526,883
|
$ 16,919,436
|
$ 11,516,325
|
|||||
License and royalty revenue
|
-
|
25,000
|
-
|
125,322
|
|||||
R&D, milestone and grant revenue
|
262,292
|
369,904
|
825,093
|
1,529,972
|
|||||
TOTAL REVENUES
|
$ 5,007,386
|
$ 5,921,787
|
$ 17,744,529
|
$ 13,171,619
|
|||||
GROSS MARGIN
|
$ 1,728,915
|
$ 2,670,733
|
$ 7,632,402
|
$ 6,647,353
|
|||||
Research and development expenses
|
$ 1,005,645
|
$ 1,242,295
|
$ 3,363,819
|
$ 3,697,309
|
|||||
Selling, general and administrative expenses
|
$ 1,208,383
|
$ 949,237
|
$ 3,521,552
|
$ 2,412,867
|
|||||
INCOME (LOSS) FROM OPERATIONS
|
$ (485,113)
|
$ 479,201
|
$ 747,031
|
$ 537,177
|
|||||
OTHER INCOME (EXPENSE):
|
$ (546)
|
$ (3,596)
|
$ (2,187)
|
$ (9,030)
|
|||||
Income tax provision (benefit)
|
$ (193,310)
|
|
$ -
|
$ 295,220
|
|
$ -
|
|||
NET INCOME (LOSS)
|
$ (292,349)
|
|
$ 475,605
|
$ 449,624
|
|
$ 528,147
|
|||
Basic earnings (loss) per share
|
$ (0.04)
|
|
$ 0.06
|
$ 0.06
|
|
$ 0.07
|
|||
Diluted earnings (loss) per share
|
$ (0.04)
|
|
$ 0.06
|
$ 0.05
|
|
$ 0.06
|
|||
Weighted average number of shares outstanding, basic
|
8,001,472
|
|
7,913,081
|
7,974,447
|
|
7,860,904
|
|||
Weighted average number of shares outstanding, diluted
|
8,001,472
|
|
8,508,740
|
8,616,917
|
|
8,644,940
|
Chembio Diagnostics, Inc. & Subsidiary
|
||||||||
Summary of Condensed Consolidated Balance Sheets
|
||||||||
September 30, 2012
|
December 31, 2011
|
|||||||
Unaudited
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$ | 3,290,565 | $ | 3,010,954 | ||||
Accounts receivable, net of allowance for doubtful accounts of $30,000 at September 30, 2012 and December 31, 2011
|
2,567,172 | 2,998,449 | ||||||
Inventories
|
3,037,880 | 2,300,286 | ||||||
Prepaid expenses and other current assets
|
705,850 | 681,893 | ||||||
TOTAL CURRENT ASSETS
|
9,601,467 | 8,991,582 | ||||||
FIXED ASSETS, net of accumulated depreciation
|
1,334,751 | 1,062,276 | ||||||
OTHER ASSETS
|
||||||||
Deferred tax asset, net of valuation allowance
|
4,483,924 | 4,749,622 | ||||||
License agreements and other assets
|
719,917 | 682,264 | ||||||
$ | 16,140,059 | $ | 15,485,744 | |||||
TOTAL CURRENT LIABILITIES
|
$ | 2,760,598 | $ | 2,857,626 | ||||
TOTAL OTHER LIABILITIES
|
95,321 | 133,484 | ||||||
TOTAL LIABILITIES
|
2,855,919 | 2,991,110 | ||||||
TOTAL STOCKHOLDERS’ EQUITY
|
13,284,140 | 12,494,634 | ||||||
$ | 16,140,059 | $ | 15,485,744 |
Chembio Diagnostics, Inc. & Subsidiary
|
||||
Summary of Condensed Consolidated Cash Flow
|
||||
UNAUDITED
|
||||
For the nine months ended
|
||||
September 30, 2012
|
September 30, 2011
|
|||
Net cash provided by operating activities
|
$ 951,742
|
|
$ 1,559,123
|
|
Net cash used in investing activities
|
(715,195)
|
|
(282,175)
|
|
Net cash provided by (used in) financing activities
|
43,064
|
|
(367,951)
|
|
INCREASE IN CASH AND CASH EQUIVALENTS
|
$ 279,611
|
$ 908,997
|
# # #
|
$O$6FN
•
|
Develops, Manufactures & Markets Point-of-care (POC) Diagnostic Tests, a $10 Billion Market
|
•
|
Partnered with Leading License & Distribution Partners in U.S. & South America
|
•
|
Oral Fluid HIV Test Pending FDA Approval
|
•
|
Pipeline Includes Syphilis, Hepatitis-C, HIV Self-Test & Potential Multiplex POC Testing Products
|
•
|
Record Revenues & Income from Operations in 2009-2011 & 2012 YTD
|
•
|
Seasoned Management Team, Strengthened in Q3 2012
|
·
|
$10B Global Point-of-Care Test (POCT) Market
|
·
|
$45B Total In-Vitro Diagnostics Market
|
•
|
Large % of Infected Individuals Not Aware of Infection
|
•
|
Has Created Large Screening Programs Globally to Reduce Transmission
|
•
|
Still 60,000 New HIV Infections in US Annually
|
•
|
Chembio’s Lateral Flow Blood Tests Sold in U.S. & Globally
|
•
|
Chembio's Patented Dual Path Platform (DPP®) Oral Fluid HIV Test Pending FDA Approval for Professional Use
|
•
|
FDA Approval Anticipated December '12
|
•
|
CLIA Waiver & Launch Anticipated 2013
|
•
|
HIV OTC (Home Use Self Testing) Market Estimated at >$250MM
|
•
|
Uniquely Positioned to Compete Against First Mover
|
•
|
Estimated US Market Launch 2015
|
–
|
Syphilis POCT Market
|
–
|
No POCT in US – First Mover
|
–
|
Estimated US Market - $75MM
|
–
|
Anticipated U.S. Multiplex Test Launch 2014
|
–
|
Hepatitis-C POCT Market
|
–
|
Estimated US Market, Based on New CDC Recommendation and New Therapeutics, $250MM
|
–
|
Key Decision Pending re: Reimbursement by ACA (Obama-Care)
|
–
|
Anticipated U.S. Market Launch 2015
|
–
|
Pursuing Other Products to Access Additional POCT Markets in the US & Globally
|
–
|
Proprietary Bio-Markers
|
–
|
New OEM and Distribution Collaborations
|
–
|
New Technologies that Complement Chembio’s Core Technology
|
•
|
Continuing YOY Sales & Market Share Growth in US Despite Public Health Funding Challenges
|
•
|
Strong 2013 Outlook
|
•
|
Significant New International Market Wins & Opportunities for Growth
|
•
|
10 Years Later, New POCT OTC Market Launch by Competitor in October 2012
|
•
|
Chembio Uniquely Positioned to Capitalize on Competitor’s Market Development Investment
|
•
|
Chembio Product Already FDA-Approved & Distributed in US (Alere) and International Professional Market
|
•
|
Pursuing FDA IDE to Begin OTC Studies in 2013, FDA Submissions 2014-2015
|
·
|
A Patented Platform Technology with a Multitude of Potential Diagnostic Applications
|
·
|
Improves Performance (Sensitivity and Specificity) v. Lateral Flow
|
‐
|
Features Independent Sample Path and Direct Binding
|
‐
|
Enables Improved Multiplex Products
|
•
|
Oswaldo Cruz Foundation (FIOCRUZ)
|
‐
|
Major Supplier to Brazilian Federal Ministry of Health Public Health Programs
|
‐
|
Aggregate of $23MM in DPP® Tech. Transfer Contracts Started in 2011
|
‐
|
>$7MM YTD and >$9MM Anticipated for FY ‘12
|
‐
|
Strong Demand Indicated for 2013, Likely Reduced in 2014
|
•
|
Possible New Products & Collaborations in Brazil with FIOCRUZ & Private Market
|
•
|
Completed 3,000 Patient Clinical Trial Q2
|
•
|
Filed Final Module with FDA in June 2012
|
•
|
PMA Approval Anticipated by End of 2012
|
•
|
CLIA Waiver/Launch in U.S. Professional Market 2013
|
•
|
Potential OTC Trials & FDA Submission 2014-2016
|
•
|
First Dual POCT for Syphilis Enables Confirmation & Treatment At POC
|
•
|
Resuming FDA Clearance Submission in Q4 2012 with Data Supporting Clinical Utility
|
•
|
Clinical Trials and FDA Submission Anticipated 2013
|
•
|
Anticipated U.S. Market Launch 2014
|
•
|
HIV-Syphilis Combo Test
|
•
|
Data Published in Journal of Clinical Virology on Chembio's Assay
|
•
|
New (July 2012) Final CDC Recommendations for an estimated 70 million Americans to be screened for HCV
|
•
|
Completed Feasibility to Establish Performance Comparable to Current Standard
|
•
|
Pursuing Differentiating Features
|
•
|
Anticipated Timeline
|
‐
|
Development & Clinical Trials – 2013-2014
|
‐
|
US Market Launch Anticipated - 2015
|
•
|
1st 9 mos. 2012 Revenues Increased 35% to $17.7MM Compared to 1st 9 mos. 2011
|
•
|
1st 9 mos. Operating Income of $.75MM Achieved by Strong DPP-Brazil & US Market Gains
|
In (000’s)
|
YTD Sept. 30, 2012
|
YTD Sept. 30, 2011
|
||
Net Product Revenues
|
$16,919
|
$ 11,516
|
||
Non-Product Revenues
|
$ 825
|
$ 1,655
|
||
TOTAL REVENUES
|
$17,744
|
$ 13,171
|
||
GROSS MARGIN
|
$ 7,632
|
43%
|
$6,647
|
50%
|
OPERATING COSTS:
|
||||
Research and Development exp
|
$ 3,364
|
19%
|
$3,697
|
28%
|
Selling, G&Administrative exp
|
$ 3,522
|
20%
|
$2,413
|
18%
|
$ 6,886
|
$6,110
|
|||
INCOME FROM OPERATIONS
|
$ 746
|
$ 537
|
||
OTHER INCOME (EXPENSES):
|
$ (2)
|
$ (9)
|
||
NET INCOME-Before Taxes
|
$ 744
|
4%
|
$ 528
|
4%
|
Income tax (benefit) provision
|
$ 295
|
$ -
|
||
NET INCOME
|
$ 449
|
3%
|
$ 528
|
4%
|
•
|
Lower Sales and Net Loss in Q3
|
•
|
Q3 Result Impacted by Large International Order Received in Q3 Completed in Q4
|
•
|
Manufacturing Inefficiencies and Product Mix Impacted Gross Profit in Q2 & Q3
|
•
|
Expect Record Revenue & Continued Profitability in Q4 and FY2012
|
•
|
Record Order Backlog at start of Q4
|
•
|
Strong Brazil Backlog for Q4 and FY2013 Outlook
|
•
|
Improved US Sales Anticipated in Q4 with Positive 2013 Budget Outlook from Alere
|
•
|
Increased International Sales Order Backlog
|
Ticker Symbol (NASDAQ)
|
CEMI
|
Price 10/31/12
|
$4.36
|
52-Week High
|
$5.30
|
52-Week Low
|
$2.96
|
Outstanding Shares
|
8.00
|
Market Capitalization
|
$34.9
|
Fully Diluted Shares
|
8.8
|
Management Holding
|
1.6
|
Average Daily Volume (3 months)
|
27,400
|
Options
|
Amt.
|
Avg. Ex. Price
|
515K held by Mgmt. & Board
|
764K
|
$2.08
|
($ in millions)
|
Sept.’12
|
Dec'11
|
Dec. '10
|
Cash
|
$ 3,290
|
$ 3,011
|
$ 2,136
|
Total Current Assets
|
9,601
|
8,992
|
7,637
|
Total Assets
|
$16,140
|
$ 15,486
|
$ 9,086
|
Total Current Liabilities
|
2,761
|
2,858
|
3,076
|
Total Liabilities
|
2,856
|
2,991
|
3,277
|
Total Equity
|
13,284
|
12,495
|
5,809
|
Total Liabilities & Stockholders’ Equity
|
$16,140
|
$ 15,486
|
$ 9,086
|
Lawrence Siebert
|
Chairman & CEO
|
2002
|
Richard Larkin
|
CFO
|
2003
|
Javan Esfandiari
|
SVP R&D
|
2000
|
Tom Ippolito
|
VP Regulatory, Clinical, QA/QC
|
2005
|
Sharon Klugewicz
|
VP QA/QC & Technical Operations
|
2012
|
Rick Bruce
|
VP Operations
|
2000
|
Michael Steele
|
VP Sales Marketing & Bus. Dev.
|
2012
|
Gary Meller, MD, MBA
|
2005
|
|
Katherine Davis, MBA
|
2007
|
|
Barbara DeBuono, MD, MPH
|
2011
|
|
Peter Kissinger, Ph.D
|
2011
|
•
|
FDA & USDA- Approved Development & Manufacturing Facility
|
•
|
28,000 Sq. Ft. Leased Facility in Medford, NY
|
Reg. & Clinical QA &QC
|
15
|
SG&A
|
11
|
Research & Development
|
29
|
Operations
|
116
|
·
|
Three Consecutive Years of Profitability and Revenue Growth
|
·
|
Strategy is to create core business of public health and women’s health products to be complemented by OEM and selected out-licensing opportunities.
|
·
|
Robust pipeline of POCT products for infectious diseases based on Chembio’s patented DPP® technology.
|
·
|
Products developed on DPP® platform include oral fluid HIV test anticipated to be reviewed by FDA during 2012. Unique Syphilis tests will be submitted and undergoing US FDA regulatory evaluations in 2012. Several other products and collaborations in pipeline.
|
·
|
Unique opportunity to participate in nascent U.S. market for OTC HIV tests with multiple product offerings.
|
·
|
Five DPP® products approved in Brazil during 2010-11 are anticipated to generate at least $9MM in 2012 revenues as compared with $4.5MM in 2011.
|
Balance Sheet Data ($000s)
|
Sept’12
|
Dec ‘11
|
Cash
|
$3,290
|
$ 3,011
|
Accts. Receivable
|
2,567
|
2,998
|
Inventories
|
3,038
|
2,300
|
Other Current Assets
|
706
|
682
|
Total Current Assets
|
9,601
|
8,991
|
Net Fixed Assets
|
1,335
|
1,062
|
Other Assets
|
5,204
|
5,432
|
Total Assets
|
16,140
|
15,486
|
Total Current Liab.
|
2,761
|
2,858
|
Total Other Liab.
|
95
|
133
|
Total Liabilities
|
2,856
|
2,991
|
Total Equity
|
13,284
|
12,495
|
Total Liabilities & Stockholders’ Equity
|
$16,140
|
$15,486
|
For the Quarter Ended/ For the Nine Months Ended/For the
|
Year Ended
|
||||||||
$(000s)
|
Q3’12
|
Q3’11
|
Q3’12
|
Q3’11
|
2011
|
2010
|
2009
|
||
Total Revenues
|
$5,007
|
$5,921
|
17,744
|
13,171
|
$19,388
|
$ 16,705
|
$13,834
|
||
Cost of sales
|
3,278
|
3,251
|
10,112
|
6,524
|
9,998
|
8,604
|
7,974
|
||
Gross Profit
|
1,729
|
2,670
|
7,632
|
6,647
|
9,390
|
8,101
|
5,860
|
||
34.5%
|
45.1%
|
43.0%
|
50.5%
|
48.4%
|
48.5%
|
42.4%
|
|||
R&D Expense
|
1,006
|
1,242
|
3,364
|
3,697
|
4,878
|
2,586
|
2,884
|
||
SG&A Expense
|
1,208
|
949
|
3,522
|
2,413
|
3,424
|
2,941
|
2,659
|
||
Operating Income
|
(485)
|
479
|
746
|
537
|
1,088
|
2,574
|
317
|
||
Other Inc. (Expense)
|
(1)
|
(3)
|
(2)
|
(9)
|
(12)
|
(15)
|
(8)
|
||
Net Income -PreTax
|
(4860
|
476
|
744
|
528
|
1,076
|
2,559
|
309
|
||
Inc. Tax(Ben.) Prov.
|
(193)
|
-
|
295
|
-
|
(5,133)
|
-
|
-
|
||
Net Income (Loss)
|
$(293)
|
$476
|
$449
|
$528
|
$6,209
|
||||
Net Income(Loss) - per Share
|
$0.04
|
$0.06
|
0.06
|
.07
|
$0.10
|
$ 0.04
|
$ 0.00
|
||
Wt. Avg. No. Shares (MM)
|
8.001
|
7.913
|
7.974
|
7.861
|
63.328
|
62.103
|
61.946
|
||
Working capital
|
$6,841
|
$5,281
|
$6,841
|
$5,281
|
6,134
|
$ 4,560
|
$ 1,494
|
||
Total assets
|
16,140
|
10,099
|
16,140
|
10,099
|
15,486
|
9,086
|
6,315
|
||
Total liabilities
|
2,856
|
3,345
|
2,856
|
3,345
|
2,991
|
3,277
|
3,227
|
||
Equity
|
13,284
|
6,754
|
13,284
|
6,754
|
12,495
|
5,809
|
3,088
|
Chembio Diagnostics, Inc.
|
Investor Relations
|
Company Contact
|
3661 Horseblock Road
|
Lippert-Heilshorn & Associates
|
Susan Norcott
|
Medford, NY 11763
|
Anne-Marie Fields, Vice President
|
631-924-1135 x125
|
Ph. 631-924-1135
|
(212) 838-3777
|
snorcott@chembio.com
|
Fax 631-924-2065
|
AFields@lhai.com
|
|
www.chembio.com
|
%LQ-C<@
M,3$P72]);F9O(#$V-B`P(%(O3&5N9W1H(#$X,"]0 P(P(-Q5NB2]I=3>RSMMA%$7!".')-QEA,ZIO
M+!&QSKZ6B.E>88G4[;25S_GP8#C.I[^/\NOKC%Q9-NY*?E4,$!+\S(_X`;_@
ME[S#K_EO_(H7?,!O^0T_X16_YZ<\O1MEY3@=]ODC+WG*[^#CX!*O,I[Q(<_Y
MF$_X(8)$PUN\^EKPM_PZO\_X9W[&O_+WO,^]^QQDUU5(E33[?,3_X,?\G-\^
MCFXS1":<"(Z.\J+//_%_HPT^SA_X%]XO!H.TY+]/BBH+58 -X=&I#V7`UN89%281DRAP@99W$NV#,YJR-!G#4U:V"D
M[!G_\VYPK.R%'-_[X%J%B8+G@$;9>R] "QC^_R1@]<;>:86F8F.%CCLAIW
M%#;)-^;R<3 <7SUZO'K*
M7TSU_?N&N[UII%@X3'[4Z,E-[]).`?C+D>(2T<-;^T+5+J+XQ>CGV\K_;O<<
M1'8KF<29H%IB_;](K=E$B=JJWUGF)3C+J!(ZAX^B7-N`U/'5=D>11&@2TRWV
MQM&+JY=S>9B,%%)]:/=$<)39>@7\OU[0JAB,JJ;>>2>A3&@0(^'.05!Z+]1O
MAOCHZQ[^):A?M"?"`.OS>W> ;?Q`?$HF">#P?6H>]G&P>V^FP.
M^DQ`WX:1..L ;[9X2*FGJ&U[*H3P7LKJJ>K\9KKK9\1
M`ZJ]?E];)OA8"RN<,]7=U6)LBU0R:(VZ@S?!9..TQ^DL4_=`Z^^_;;S5[$P.
M7O2D=1S=;V/"O&6LQ7;]G@G:KHN0[5.UWS;"8`U]7;(]$]`O-1.89\[K4V,U
MQGR>:S0REI\K">4:^;H@/Q0U7J?6!EI+JS%9),Q<4>F+<=Y\0!,\P1M0;0\K
M]"]"J4H$Y%U]3=@>4):XU`E#?&\M)L,#;T<[3N<<<(XOA#P3T`\?63!UC\-P
M]%5OBT=YPE`O=911]@^D;=$B!)`?9M/>F8!Z3Y?7[8]7377T>D6Z>MK17\0'
MA-K?N,4#Z_U^&JR`-P:X_9OXD-"#,0B*OL>#">/DF&BT:'XB>/@I7Q<(ECI,
MW_`%BQ]#&OI,0#^OH,+78U\(]]WAP73Q";\NS@H*W'WN1F-NNVNF`ID)Z#F6
MQOM'E&[)&81%F2VB2S'_$'PQ_:Z'`A<9]'Y'^=/7JM8B$RR0"M0^D6V6T3EM
MHU),;=>V,GTF6""OGG5F#*[?>\^YLY=Q:^1#,-GVI04K4Q3C/OP`>">_F["^
MF&K%/1NYCG028ZK:M`X8DXGZLH=0NB.FLSCF'<@> >)\9&3@E`DS.M;&.F_T5`
MOOA_GQ;_GS(^ALR`O>HL3GDF()]%IQW8;ZPN6`'UT25/&.K1Y3K'[J.-KVL#
M5BU&W[T)Z*,>)KW?JXE(7"@8/)L.GPGH[7K#*2A3OL5A^J2YMF1^)J#OW;.W
MV^;^*#Q++R%N1OI,0%\78RU*3WR7,[L#*A(ZV^(7IKKQ,GK!WXL6ZURLV-3?
MC?),0%_HO'[NU*9R;\`-J#\S<%[X`_RU9L;?UZ8G(_ER8@,JC>I,?$APMTIU
MH>.:"78MMB5/!.13NT5)GNI6OK9,146_\DQ0?N^MXNA386!GO@Q8]2:*SIX)
MZ,=^7E'`^;S@R=H0?ZY4)TSQ?;`.7[D\@1@ZT*XM@_),0*]\88;_ZVO?N#5;
M\L30T3,!M;FBQ&&LM>N:$;`O+6>ZN$Q`W]M2E$'?[L5N>++I!;>UJ,\$].4&
MRH+YY3ZI@?UO+HTF!OI,'/TX<7B?_,D10^/2R>8%5U<4**O)_DQP_Z[R$\U9
M@N-!IW:9G)^)SXO@=OU6/LI=E?&[>R(HGT.UDWIU6ZV^T/?PB?AD`I4ZEF?+
M8D5Z]@%V+S\3U*MT>\/AJ]HO'68\S9?D#T&YL2>*CC9\[^H[HF\Y4,[P@73W
M)G!W:W%#C].?V6JO[_>`?ANX07TFH!\2V!E7`D[V37U!S^IP8&_49P+Z>*[P
MY\#^KJZMK$T]5R],F&^"^ROV]L3YQXV=2G/T%!?]]R:H5[`N_G\Q; JYBX!#P]4FW.KB
MT1C^(:"OC6]5C@,&W'NI]X=\C!1>0%D1\DYWCQ[<_5X
MW'>X%4KV^#?Q":)VE5H$VZ$J-VK!(>>/_QL_S[789P7]MMD'
M0SPWG9^#;9V^S!
M/A/0KT)B5&Q]<6
MMR'K@`;AP(#T0WR